

## Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

November 13, 2020

Corporate Relationship Department M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Scrip Code: 524816

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai</u> 400 051

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

MAnocrayana M. Adinarayana

Company Secretary &

Vice President (Legal and Corp Affairs



## **Natco Pharma Limited**

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

PR/11/2020-2021

**Press Release** 

## NATCO receives Pomalidomide approval for US market

Hyderabad, India, November 13th, 2020

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc., has received final approval for its Abbreviated New Drug Application (ANDA) for Pomalidomide Capsules, from the U.S. Food and Drug Administration (USFDA). In addition, NATCO and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the U.S. district court for this product.

Celgene, sells Pomalidomide Capsules under Brand name POMALYST®, in the USA market which is indicated for the treatment of patients suffering from multiple myeloma cancer. As per industry sales data, POMALYST® had annual sales of \$957 million during the twelve months ending September 2020.

Forwarded for favour of publication For NATCO Pharma Limited

M Adinarayana

Company Secretary &

Vice President (Legal & Corp. Affairs)